Evidence map›Paper›PMID 31570832›Full record

ReviewNature reviews. Cardiology2019

Looking back and thinking forwards - 15 years of cardiology and cardiovascular research.

Jonathan M Kalman, Sergio Lavandero, Felix Mahfoud, Matthias Nahrendorf, Magdi H Yacoub, Dong Zhao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Precision percutaneous coronary intervention.NPJ cardiovascular health · 2026
    Review
  2. Artificial intelligence in heart failure.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Precision cardiology in the digital era.Nature reviews. Cardiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 8 countries.

Jonathan M KalmanDepartment of Cardiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. jon.kalman@mh.org.au.
Sergio LavanderoAdvanced Center for Chronic Diseases (ACCDiS), Faculty of Chemical and Pharmaceutical Sciences & Faculty of Medicine, University of Chile, Santiago, Chile. slavander@uchile.cl.ORCID http://orcid.org/0000-0003-4258-1483
Felix MahfoudDepartment of Internal Medicine III, Saarland University Hospital, Homburg (Saar), Germany. felix.mahfoud@uks.eu.
Matthias NahrendorfCenter for Systems Biology, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. mnahrendorf@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-4021-1887
Magdi H YacoubNational Heart and Lung Institute, Heart Science Centre, Harefield Hospital, London, UK. m.yacoub@imperial.ac.uk.
Dong ZhaoCapital Medical University, Beijing Anzhen Hospital, Beijing, China. deezhao@vip.sina.com.
Advanced Center for Chronic Diseases · CLCapital Medical University · CNHarefield Hospital · GBInstitute for Medical Research · MYMassachusetts General Hospital · USThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first issue of Nature Reviews Cardiology was published in November 2004 under the name Nature Clinical Practice Cardiovascular Medicine. To celebrate our 15th anniversary in 2019, we invited six of our Advisory Board members to discuss what they considered the most important advances in their field of cardiovascular research or clinical practice in the past 15 years and what changes they envision for cardiovascular medicine in the next 15 years. Several practice-changing breakthroughs are described, including advances in procedural techniques to treat arrhythmias and hypertension and the development of novel therapeutic strategies to treat heart failure and pulmonary arterial hypertension, as well as those that target risk factors such as inflammation and elevated LDL-cholesterol levels. Furthermore, these key opinion leaders predict that machine learning technology and data derived from wearable devices will pave the way towards the coveted goal of personalized medicine.

Identifiers

PMID31570832
OpenAlexW2975586941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.